GlassScriptPhysician profile
Joan M Allmon
NPI 1073516852
$12,687.13
in general payments reported to CMS, 2019-2025
57 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $1,784 · 2021: $2,113 · 2022: $1,658 · 2023: $1,617 · 2024: $2,035 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.09 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,321.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,611.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,443.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $678.38 | 2019-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $654.80 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $539.30 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $507.85 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $341.94 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $316.35 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $303.84 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $292.93 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.94 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $195.93 | 2019-2025 | Livalo, Zoryve |
| Sanofi-Aventis U.S. LLC | $195.93 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.68 | 2021-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Allmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.